Savas Hulya, Ozkol Hatice Uce, Gorgisen Gokhan, Özkol Halil, Ates Can, Metin Ahmet, Özdemir İlknur Yorgun
Department of Dermatology, Erzincan State Hospital, Erzincan, Turkey.
Department of Dermatology, Faculty of Medicine, Yuzuncu Yil University, Van, Turkey.
Postepy Dermatol Alergol. 2024 Aug;41(4):357-363. doi: 10.5114/ada.2024.142285. Epub 2024 Aug 14.
Chronic urticaria requires well-defined treatment strategies in order to achieve a maximum treatment response and maintain the quality of life. Since 2014, omalizumab has been used in chronic urticaria. However, many studies showed that some patients are resistant to omalizumab.
To determine the effects of single nucleotide changes in the and genes, which are thought to be related to resistance mechanisms, in our population of patients who have not responded to omalizumab treatment.
We included 100 patients with chronic urticaria who were treated with omalizumab and 50 healthy individuals. Frequently observed gene polymorphisms, FCER1A (rs2251746) and FCER1B (rs569108), were examined in peripheral blood samples. The regions of rs2251746 and rs569108 gene polymorphisms were amplified using fluorescently labelled probes through real-time polymerase chain reaction (PCR). The analysis was performed bioinformatically via the SNP genotype profiling program.
There was no statistically significant relationship between (rs2251746) and (rs569108) gene polymorphisms in patients and their clinical, demographic characteristics, and the resistance to treatment ( > 0.05). In our study, the mean patient age was found to be higher in the CT group (44.71 ±12.5 years) compared to the TT group (37.34 ±11.5 years) only in the rs2251746 polymorphism ( < 0.05).
In our study, there was no significant relationship between and gene polymorphisms and resistance to omalizumab therapy. Further, multicentre, large-scale studies are needed to support our results.
慢性荨麻疹需要明确的治疗策略，以实现最大的治疗反应并维持生活质量。自2014年以来，奥马珠单抗已用于治疗慢性荨麻疹。然而，许多研究表明，一些患者对奥马珠单抗耐药。
确定在我们未对奥马珠单抗治疗产生反应的患者群体中，与耐药机制相关的 和 基因的单核苷酸变化的影响。
我们纳入了100例接受奥马珠单抗治疗的慢性荨麻疹患者和50名健康个体。对外周血样本中经常观察到的基因多态性，即FCER1A（rs2251746）和FCER1B（rs569108）进行检测。通过实时聚合酶链反应（PCR），使用荧光标记探针扩增rs2251746和rs569108基因多态性区域。通过SNP基因型分析程序进行生物信息学分析。
患者的 （rs2251746）和 （rs569108）基因多态性与其临床、人口统计学特征以及治疗耐药性之间无统计学显著关系（P>0.05）。在我们的研究中，仅在rs2251746多态性中，发现CT组（44.71±12.5岁）的患者平均年龄高于TT组（37.34±11.5岁）（P<0.05）。
在我们的研究中， 和 基因多态性与奥马珠单抗治疗耐药性之间无显著关系。此外，需要多中心、大规模研究来支持我们的结果。
